96 related articles for article (PubMed ID: 26902334)
61. A non-invasive approach for NEPC diagnosis.
Masone MC
Nat Rev Urol; 2022 Feb; 19(2):67. PubMed ID: 35031785
[No Abstract] [Full Text] [Related]
62. Cancer cell evolution through the ages.
Maley CC; Shibata D
Science; 2019 Aug; 365(6452):440-441. PubMed ID: 31371596
[No Abstract] [Full Text] [Related]
63. Genomic Aberrations Drive Clonal Evolution of Neuroendocrine Tumors.
Kaushik AK; Sreekumar A
Trends Endocrinol Metab; 2016 May; 27(5):242-244. PubMed ID: 27037211
[TBL] [Abstract][Full Text] [Related]
64. Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer?
Taplin ME; Balk SP
JAMA Oncol; 2015 Aug; 1(5):577-9. PubMed ID: 26181796
[No Abstract] [Full Text] [Related]
65. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
[TBL] [Abstract][Full Text] [Related]
66. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
Beltran H; Prandi D; Mosquera JM; Benelli M; Puca L; Cyrta J; Marotz C; Giannopoulou E; Chakravarthi BV; Varambally S; Tomlins SA; Nanus DM; Tagawa ST; Van Allen EM; Elemento O; Sboner A; Garraway LA; Rubin MA; Demichelis F
Nat Med; 2016 Mar; 22(3):298-305. PubMed ID: 26855148
[TBL] [Abstract][Full Text] [Related]
67. Prostate cancer: Multilayered mutation analysis indicates divergent clonal evolution.
Thoma C
Nat Rev Urol; 2016 Apr; 13(4):179. PubMed ID: 26902334
[No Abstract] [Full Text] [Related]
68. Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.
Buonerba C; Di Lorenzo G; Sonpavde G
Expert Rev Mol Diagn; 2016 Oct; 16(10):1113-1120. PubMed ID: 27665838
[TBL] [Abstract][Full Text] [Related]
69. [Hormone Resistance and Neuroendocrine Differentiation Due to Accumulation of Genetic Lesions during Clonal Evolution of Prostate Cancer].
Mikhaylenko DS; Efremov GD; Sivkov AV; Zaletaev DV
Mol Biol (Mosk); 2016; 50(1):34-43. PubMed ID: 27028809
[TBL] [Abstract][Full Text] [Related]
70. [Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer].
Ripert T; Crouzet S; Ploussard G; De La Taille A; Robert G
Prog Urol; 2013 Oct; 23 Suppl 1():S16-22. PubMed ID: 24314735
[TBL] [Abstract][Full Text] [Related]
71. [Molecular biology of castration-resistant prostate cancer].
Doucet L; Terrisse S; Gauthier H; Pouessel D; Le Maignan C; Teixeira L; Culine S
Bull Cancer; 2015 Jun; 102(6):497-500. PubMed ID: 26028493
[TBL] [Abstract][Full Text] [Related]
72.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
73.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
74.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
75.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
76.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]